Recruiting Heart Attack Studies in Heidelberg
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematologica...
About Heart Attack Clinical Trials in Heidelberg
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 2 heart attack clinical trials recruiting participants in Heidelberg, VICTORIA. These studies are seeking a combined 385 participants. Research is being sponsored by Amgen, AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Heidelberg — FAQ
Are there heart attack clinical trials in Heidelberg?
Yes, there are 2 heart attack clinical trials currently recruiting in Heidelberg, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Heidelberg?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Heidelberg research site will contact you about next steps.
Are clinical trials in Heidelberg free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Heidelberg studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 2 active trials in Heidelberg are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov